Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Biostar initiates phase I/II trial of Norelin in prostate cancer patients and creates subsidiary

Feb. 19, 1999

Ontak available this month in U.S.

Feb. 16, 1999

Review supports hCG as a target for cancer immunotherapy

Feb. 15, 1999

Ligand purchases Marathon Biopharmaceuticals' assets

Feb. 15, 1999

PSP94 suppresses prostate cancer growth in mouse model

Feb. 12, 1999

Enrollment completed in Maxim's malginant melanoma phase III trial

Feb. 9, 1999

Ligand receives FDA approval for Ontak as CTCL treatment

Feb. 8, 1999

ImmunoGen and SB enter agreement for colorectal cancer treatment

Feb. 4, 1999

Phase I clinical trial of novel cervical dysplasia Rx from StressGen

Feb. 3, 1999

SWOG phase II study of safety and efficacy of rhIL-4 in malignant melanoma

Jan. 25, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...